ZimVie (NASDAQ:ZIMV - Get Free Report) announced its earnings results on Wednesday. The company reported $0.08 earnings per share (EPS) for the quarter, Zacks reports. The company had revenue of $118.20 million during the quarter. ZimVie had a negative net margin of 51.33% and a positive return on equity of 2.44%. During the same quarter in the previous year, the firm posted $0.25 EPS. ZimVie updated its FY 2024 guidance to 0.550-0.700 EPS.
ZimVie Trading Up 10.3 %
Shares of NASDAQ:ZIMV traded up $1.59 during trading on Thursday, reaching $16.97. The stock had a trading volume of 950,507 shares, compared to its average volume of 342,372. The business has a fifty day moving average price of $16.40 and a 200-day moving average price of $15.01. The company has a quick ratio of 2.32, a current ratio of 2.78 and a debt-to-equity ratio of 1.26. The stock has a market cap of $461.92 million, a P/E ratio of -1.15 and a beta of 2.17. ZimVie has a fifty-two week low of $6.52 and a fifty-two week high of $20.91.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the stock. Needham & Company LLC restated a "hold" rating on shares of ZimVie in a research report on Thursday. Barclays lifted their target price on shares of ZimVie from $13.00 to $16.00 and gave the stock an "underweight" rating in a research report on Tuesday, March 5th.
Check Out Our Latest Stock Report on ZIMV
ZimVie Company Profile
(
Get Free Report)
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Featured Articles
Before you consider ZimVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ZimVie wasn't on the list.
While ZimVie currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
